{
    "2018-04-10": [
        [
            {
                "time": "",
                "original_text": "[买入评级]泰格医药(300347)：一季度高速增长 低基数与基本面共振",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "一季度",
                        "高速增长",
                        "低基数",
                        "基本面"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药：一季度利润大幅提升 买入评级",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "一季度",
                        "利润",
                        "大幅提升"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}